DJI Demonstrates Drone Technology's Potential To Unlock U.S. Job Growth Across Agriculture Industry
DJI Agriculture Pledges to Make Agras Drones More Accessible to the U.S. Market at 2025 Spray Drone End User Conference SHENZHEN, China, March 26, 2025 /PRNewswire/ -- DJI, the world leader in civilian drones and creative camera technology,...
TOYO Co., Ltd Announces Plans for Additional 2GW Solar Cell Capacity Expansion in Ethiopia
TOKYO, March 26, 2025 /PRNewswire/ -- TOYO Co., Ltd (Nasdaq: TOYO) (OTC: TOYWF) ("TOYO" or the "Company"), a solar solution company, is excited to announce it will begin building an additional 2 gigawatts (GW) expansion of its solar cell capacity at...
SHEIN Supplier Community Empowerment Program - Continuing the Drumbeat of Support
SINGAPORE, March 26, 2025 /PRNewswire/ -- SHEIN has been consistently building a program of support for our supply chain partners, the Supplier Community Empowerment Program (SCEP), looking at enhancing physical facilities and developing innovative...
Peijia Medical Announces 2024 Annual Results
HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ended...
NetDragon Announces 2024 Annual Financial Results, Fully Embraces the World of Artificial Intelligence
Profit Before Tax Up 19% YoY Final Dividend Increased by 25% YoY to HK$ 0.5 Per Share HONG KONG, March 26, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 0777), a global leader in...
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a...
ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024
Notable Progress in R&D and Commercialization Gross Profit Surging 68% FINANCIAL HIGHLIGHTS • Revenue was approximately RMB1,933.0 million, representing a year-on-year increase of 25.5%. • Gross profit was approximately RMB1,273.7 million,...
Innovent Announces 2024 Annual Results and Business Updates
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops,...